Persons with cancers are more likely to be affected by SARS-CoV-2 infection: it has been estimated that there is an increased risk of 1% [95% CI 0.6–1.7%] compared to 0.1% of normal [95% CI 0–0.12%] [1]. Several controversies on this topic emerged and the real potential risk in different cancer types remains unclear [2, 3]. A cohort study conducted in two Chinese centers in Wuhan on 128 hospitalized hematological cancer patients showed that 13 (10%) of them developed COVID-19 infection. No differences in baseline features were noted between subjects with hematological cancers that developed the infection and patients who did not. Among patients tested positive for COVID-19 (no patients with myeloproliferative disorders reported), the incidence was similar to normal healthcare providers (7%) but the mortality rate was increased to 62% as compared to 0% of these latter category [4]. Recently, the Chinese group of Hubei reported also the prevalence of COVID-19 infection (0.9%) in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients, that resulted ninefold higher than 0.1% reported in normal, but lower if compared to 10% in other hematological malignancies or 7% in healthcare providers [5]. The low rate of COVID-19 infection in CML was recently confirmed in Italy [6]. At present, is still unclear the prevalence of COVID-19 infection in Philadelphia-negative myeloproliferative disorders (MPN) and the role of JAK2 inhibitor, ruxolitinib, a drug successfully used in myelofibrosis and polycythemia vera, implicated in modulation and reduction of cytokines release.

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey / Breccia M.; Piciocchi A.; De Stefano V.; Finazzi G.; Iurlo A.; Fazi P.; Soddu S.; Martino B.; Palandri F.; Siragusa S.; Albano F.; Passamonti F.; Vignetti M.; Vannucchi A.M.. - In: LEUKEMIA. - ISSN 0887-6924. - ELETTRONICO. - 34:(2020), pp. 2813-2814. [10.1038/s41375-020-01032-0]

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

Palandri F.;Albano F.;Vannucchi A. M.
2020

Abstract

Persons with cancers are more likely to be affected by SARS-CoV-2 infection: it has been estimated that there is an increased risk of 1% [95% CI 0.6–1.7%] compared to 0.1% of normal [95% CI 0–0.12%] [1]. Several controversies on this topic emerged and the real potential risk in different cancer types remains unclear [2, 3]. A cohort study conducted in two Chinese centers in Wuhan on 128 hospitalized hematological cancer patients showed that 13 (10%) of them developed COVID-19 infection. No differences in baseline features were noted between subjects with hematological cancers that developed the infection and patients who did not. Among patients tested positive for COVID-19 (no patients with myeloproliferative disorders reported), the incidence was similar to normal healthcare providers (7%) but the mortality rate was increased to 62% as compared to 0% of these latter category [4]. Recently, the Chinese group of Hubei reported also the prevalence of COVID-19 infection (0.9%) in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients, that resulted ninefold higher than 0.1% reported in normal, but lower if compared to 10% in other hematological malignancies or 7% in healthcare providers [5]. The low rate of COVID-19 infection in CML was recently confirmed in Italy [6]. At present, is still unclear the prevalence of COVID-19 infection in Philadelphia-negative myeloproliferative disorders (MPN) and the role of JAK2 inhibitor, ruxolitinib, a drug successfully used in myelofibrosis and polycythemia vera, implicated in modulation and reduction of cytokines release.
2020
34
2813
2814
Breccia M.; Piciocchi A.; De Stefano V.; Finazzi G.; Iurlo A.; Fazi P.; Soddu S.; Martino B.; Palandri F.; Siragusa S.; Albano F.; Passamonti F.; Vignetti M.; Vannucchi A.M.
File in questo prodotto:
File Dimensione Formato  
s41375-020-01032-0.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 315.18 kB
Formato Adobe PDF
315.18 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1257220
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 14
social impact